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9INTRODUCTION
Normal hemostasis provides a free flow of blood in body vessels. When there is interference an
effective and rapid repair system is activated and provides the prerequisites for the following events,
such as wound healing. This vital system comprises three major components: 1) platelets, that
normally circulate in the blood but become adhered and activated to each other or to the blood
vessel walls when needed to stop the bleeding 2) a coagulation cascade, which is a complex system
of molecules aimed to secure the stability of the formed platelet thrombus 3) the endothelium,
which contains various agents that participate in the initiation of hemostasis as well as take care of
further wound healing process.
There are various reasons, which may sway the hemostatic scale towards pathological events:
bleeding or thrombosis. The severity of clinical manifestation often vary dramatically depending
much on the causative factors. These include acquired defects that may be caused by such factors as
bad life style or environment, and inherited ones. Bleeding diseases are usually monogenic, whereas
thrombotic disorders mainly have a multifactorial background, especially in arteries. Fatal bleeding
disorders are fairly rare in populations, in contrast to pathological thrombus formation, which is the
most dominant cause of morbidity and mortality in our society nowadays. In order to develop and
maintain educational programs for life style and new treatments it is necessary to understand details
of the pathogenesis of the diseases. This aim may be reached by going to the basis of the processes
at the molecular level.
In this study, we have investigated the biology of three molecules apparently acting in hemostatic
processes and contributing by different ways to various disease processes. Coagulation factor XIII
(FXIII) is the last enzyme of the coagulation cascade and its main function is to stabilize the
forming clot. It has been known for several decades that lack of this enzyme causes a severe
bleeding diathesis. However, its role in thrombogenic disorders has not been studied until very
lately. The other two molecules of interest are vascular endothelial growth factors VEGF and
VEGF-C. Although the exact functions of them in hemostasis have not been solved yet, it is clear
that being endothelilal cell growth factors with angiogenic and vascular permeability inducing
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properties, they take part in multiple events occurring intravascularly. This work focuses on the
molecular aspects of FXIII, VEGF and VEGF-C in relation to thrombosis.
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REVIEW OF THE LITERATURE
1. Thrombophilia
The term of thrombophilia is used to describe a patient’s tendency to pathological thrombus
formation. There are multiple causes of thrombophilia which may be divided into subgroups by
various ways (Table 1). The most obvious division of the causes is into inherited and acquired
forms. The inherited/genetic forms comprise defects in the proteins functioning in the responses of
an endothelial injury (coagulation, platelet modifications, endothelium), whereas life style or drugs
are included in the acquired category of risks. Here, the focus is laid on genetic aspects influencing
thrombophilia.
When the power of hemostatic factors exceeds the inhibitory threshold of an individual’s
endogenous anticoagulant mechanisms the formation of a pathological thrombus occurs. This may
be reflected in the levels of several hemostatic variables (Ernst et al. 1993, Meade et al. 1986,
Ridker et al. 1993, Hamsten et al. 1987, Kannel et al. 1995, Schaefer et al. 1994). We are living in
the era during which concentrated efforts have been exerted on characterization of the genetic
reasons for these variations and indeed, multiple mutations and polymorphisms have already been
found. By conferring sensitivity to environmental factors, such gene variations may affect the gene
expression and protein concentrations. Mutations or polymorphisms in the coagulation factor V
(FV), antithrombin III, protein C and S, plasminogen activator inhibitor-1 (PAI-1) or tissue type
plasminogen (tPA) genes are known to lead to impairment of the negative regulation of thrombosis.
Furthermore, polymorphisms in the coagulation factor VII (FVII) and prothrombin genes have been
identified to directly increase the potency of the coagulation (reviewed by Di Minno et al. 1997, Wu
1997, Bauer et al. 1998, and Rao et al. 1998).
Only very few genetic variations shown to be protective against pathological thrombus formation
have been reported (Green et al. 1991, Iacovello et al. 1998). Interestingly, a common mutation
(Val34Leu) in the coagulation factor XIII gene has very recently been suggested to be included in
this small group of beneficial component affecting multifactorial thrombotic diseases (Kohler et al.
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1998, original publication I, Catto et al. 1999, Franco et al. 1999). Coagulation factor XIII (FXIII)
acts in the very last steps of the coagulation cascade and lack of a functional enzyme due to
mutations in FXIII gene causes a bleeding disorder (reviewed by Seitz et al. 1996). However, it has
been shown that the Val34Leu polymorphism does not associate with bleedings and the mechanism
by which it affects thrombophilia needs further studies.
Thrombosis is a multifactorial disease and often results from an interaction of various risk factors.
An example of this was reported e.g. in a recent study where an additive effect on thrombophilia
was shown to be associated with an interaction of 4G/4G polymorphism in PAI-1 gene promoter
and hereditary protein S deficiency (Zöller et al. 1998). The combined effects of risks (genetic-
genetic, acquired-genetic, as well as acquired-acquired) may also be synergistic. This can be
demonstrated for example in the interactions of factors causing activated protein C resistance, such
as Arg506Gln mutation in the coagulation factor V gene, also called FV Leiden, and oral
contraceptives (De Stefano et al. 1998). FV Leiden is a strongly thrombophilic mutation, which
seems to be prevalent only in Caucasian races (Bertina et al. 1994). The allele frequency of FV
Leiden in the Finnish population varies from 2-3%, which is of the same order of magnitude with
Iceland, Spain, European Russia, and The Netherlands (Kontula et al. 1995, De Stefano et al. 1998,
original paper II). The heterozygous carriers of FV Leiden have been demonstrated to have a 7-fold
risk for deep venous thrombosis (DVT) compared to the wild types. The use of oral contraceptives
increases the risk by 4. However, together they cause a 35-fold increase in risk to acquire a DVT.
Interestingly, for individuals being homozygous for FV Leiden the risk factor yields 80 even without
additional acquired factors such as oral contraceptives (Vandenbroucke et al. 1994, De Stefano et al.
1998, Bauer et al. 1998).
The conditions for blood flow in the arterial system are distinct from the venous ones, which leads
to a distinction between the risk factors directed to one or the other side of the vascular system.
However, there are exceptions, such as hyperhomocysteinemia, sticky platelet syndrome, and -based
on very recent results- possibly FXIII Val34Leu polymorphism, that seem to act dually (Boers 1997,
Bick et al. 1998, Kohler et al. 1998, Catto et al. 1999, Franco et al. 1999).
The new generation of genetic markers of thrombophilia provide important tools for assessing the
biochemical basis for the hemostatic imbalance leading to patients’ procoagulant states in vivo,
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sometimes even prior to the appearance of thrombotic episodes. They have provided one of the first
clear cut models of complex diseases where the effects of multiple gene defects and their interplay
with environmental risk factors accumulate.
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Table 1. Examples of acquired and inherited risks for thrombophilia. The factors identified to be
associated with gene variations are marked with ✶.
        Clinical Conditions /
Arterial
    Clinical Conditions/
Venous
        Plasma Protein/Platelets
Atherosclerosis ✶ Malignancy ✶ Antiphospholipid syndrome ✶
Cigarette smoking Surgery Activated protein C resistance ✶
Hypertension ✶ Trauma TGF-β1
Diabetes Mellitus ✶ Immobility Protein S defects ✶
Low-density lipoprotein
cholesterol ✶
Sepsis
Obesity ✶
Protein C defects ✶
Sticky platelet syndrome ✶
Hypertriglyceridemia ✶ Oral contraceptives Antithrombin defects ✶
Positive family history ✶ Pregnancy Factor VII and VIII alterations ✶
Oral contraceptives PAI-1 alterations ✶
Lipoprotein (a) ✶ tPA defects ✶
Insulin resistance ✶ Factor XII defects ✶
Infection ✶ Dysfibrinogemia ✶
Essential thrombocytemia Homocysteinemia ✶
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2. Hemostatic response to endothelial injury
An endothelial injury induces activation of an effective repair system in order to maintain the
hemostatic balance that is essential for health. A dysfunction caused by for example genetic defects
in the components of the repair system, may lead to a clinical thrombophilia as well as bleeding
diathesis.
Whenever the vessel wall is severed, the luminal subendothelial elements become exposed and
come into contact with blood components. Immediately, a simultaneous vasoconstriction, adhesion
and activation of platelets to the vessel wall, as well as activation of the coagulation cascade and
marginating endothelial cells, occurs at the damage site. The specific responses of platelets, the
coagulation cascade and endothelium reflecting hemostatic repair system are reviewed.
2.1 Platelet modifications
Platelets essentially contribute to the maintenance of vascular integrity and control of hemorrhage
after injury. They can be activated by a variety of physiological (thrombin, thromboxane (Tx) A2,
collagen, von Willebrand factor (vWF), adenosine diphosphate (ADP), platelet activating factor
(PAF) etc.) and pharmacological agents (calcium ionophores, cyclic endoperoxide analogs etc.)
(reviewed by Blockmans et al. 1995). The effects of these activators are exerted through interactions
with specific receptors on the platelet plasma membrane. Both strong and weak agonists for platelet
activation are found. Strong ones, such as thrombin and collagen have a primary role in the
activation, whereas some of the weak ones including ADP, which is located in platelet dense bodies,
are secreted during platelet aggregation, and have a supportive role in the ongoing activation process
(Brass 1994).
Adhesion of platelets to the vessel wall and to each other occurs subsequent to the exposure of
subendothelial particles in the injured wall (Figure 1). Blood flows with an increased velocity near
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the vessel wall compared to the more centric parts of the lumen resulting in tension and
compression to the particles in and near the wall. This effect is called shear stress, reviewed by
Kroll et al. (1996). Circulating cells, including anucleated platelets, tend to move with the layer of
fluid adjacent to the vessel wall, that provides conditions for the formation of adhesive bonds on the
reactive surfaces. The adhesion mediating receptors on the platelet surface become activated when
platelets begin to adhere to the damaged vessel wall and roll over the exposed endothelium due to
torque imposed by the flowing fluid. Platelets form a layer that occupies a position analogous to the
endothelium with respect to leukocyte accumulation. Colocalization of platelets and leukocytes at
the sites of vascular injury is found especially at sites of hemorrhage, atherosclerotic lesions and
areas of myocardial infarction (Diacovo et al. 1996).
VWF has a central role in mediating the adhesion and further platelet plug formation. Platelets
attach first to the subendothelium through interactions of the GP Ib-IX-V complex, and IIbIIIa (also
called integrin αIIbβ) with vWF and fibrin, respectively (Ikeda et al. 1991, Cines et al. 1998). The
binding to vWF exposed on injured endothelium occurs optimally in high shear stress conditions.
The absence or impaired function of vWF causes defective adhesion of platelets and the most
common inherited bleeding disorder (Sadler et al. 1994, 1995). In addition to vWF and fibrin, a
wide variety of other important molecules contributing to adhesion are found in the extracellular
matrix and platelets. These include e.g. collagen, thrombospondin, fibronectin, vitronectin, and
laminin. Many of the receptors triggering the adhesion are members of integrin or selectin families,
which are broadly distributed cell-surface molecules with certain family designated structural,
immunochemical, and functional properties (Hynes et al. 1987, Ginsberg et al. 1988, Celi et al.
1997).
Platelets are the major source of several molecules being essential in response to endothelial injury.
These molecules include such as PAF, ADP, thrombospondin, fibrinogen, fibronectin, interleukin-1
(IL-1), IL-3, and IL-6. They affect e.g. the continuing interplay between platelets and leukocytes at
the site of injury. Additionally, platelets have been shown to contain and release angiogenic,
endothelial or mesenchymal cell growth promoting agents, such as basic fibroblast growth factor
(bFGF), platelet-derived growth factor (PDGF) and VEGF (reviewed by Kumar et al. 1998,
Wickenhauser et al. 1995, Jones et al. 1992, Möhle et al. 1997, Verheul et al. 1997). When
17
delivered from platelets to the sites of vascular injury these growth factors are suggested to have an
important role in tissue repair being inductors of angiogenesis and chemotactic for various agents
needed in the process (Nissen et al. 1998). Upon activation, platelets lose their discoid shape and
become relatively spherical with long spiky pseudopods and surface protrusions. The specific
storage granules (dense bodies and α-granules) containing the various agents discussed above, move
towards the platelet center along other organelles within a constricting microtubular coil. The
granules are fused with the surface connected canalicular system (SCCS) and secretion occurs
through the widened pores of the SCCS on the plasma membrane (reviewed by Isenberg and
Bainton 1994). Simultaneously with the platelet activation, the so called flip-flop phenomenon
occurs, as the negatively charged phospholipds of platelet plasma membrane re-orientate and further
provide a catalytic surface for the activation of serine-proteases acting in the coagulation cascade.
The formation of the thrombus, that is supposed to seal the injury, continues as fibrin, the end
product of the coagulation cascade, becomes cross-linked over the aggregated platelets by FXIII.
The formed mesh of fibrin molecules acts as a clot stabilizing cement. Gradually, as time passes,
clot retraction occurs as the luminal size of the thrombus restricts. This draws the edges of the
wound together. The clot retraction is mediated by the interaction of glycoprotein IIbIIIa (GPIIbIIIa)
with cytoskeletal actin and possibly with talin as well as vinculin (Philips et al. 1980, Horwitz et al.
1986, Isenberg et al. 1994, Blockmans et al. 1995).
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ADP
TXA2
PAF
ADP
ProthrombinThrombin resting platelet
activated platelet
  endothelial cell
tissue factor
  von Willebrand factor
collagen
ADP   Adenosine diphosphate
TxA2    Thromboxane A2
PAF     Platelet activating factor
Figure 1. Upon exposure of an injured endothelium, platelets are activated by such agents as TXA2,
ADP, PAF and thrombin (produced mainly by the coagulation cascade) and they become discoid.
An effective adhesion to the damage site occurs and further hemostatic events take place. (Modified
from Brass et al. 1994)
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2.2 Coagulation cascade
The coagulation cascade is the second of the three major components acting in response to
endothelial injury. It was first described over thirty years ago (Davie and Ratnoff, 1964). Being a
very complex system, the theories on its intrinsic entity are still changing. However, there are no
doubts of the importance of the coagulation cascade in the hemostasis leading to an endpoint of a
stabilized clot. This is indicated by the severe bleeding disorders resulting from genetic deficiencies
of coagulation factors. On the other hand, mutations of the regulators of the coagulation cascade or a
coagulation factor may also result in thrombophilia.
The coagulation cascade consists of an intrinsic pathway, so named originally, because the
presumed initiative components were present in blood, and an extrinsic pathway, which requires
subendothelial tissue factor (TF) for its activation (Figure 2). The two pathways converge at the
formation of FXa by activated FIX (from intrinsic pathway) and FVII (from extrinsic pathway),
which leads to thrombin formation. In the original theory, the intrinsic pathway was thought to carry
the main responsibility for the initiation of the coagulation cascade. However, nowadays it is
generally accepted that the tissue factor pathway acts as a ”prima ballerina” in the initiation, and the
intrinsic pathway plays a more important role in the continuity of the coagulation (Luchtman-Jones
and Broze 1995, Schmaier 1997).
The extrinsic pathway or tissue factor pathway is activated as the disruption of a vessel wall exposes
TF to circulating plasma components factor VII or VIIa (reviewed by Bauer 1997). They form a
complex, which proteolytically activates factors IX and X. Some of factor Xa proceeds to catalyze
the conversion of prothrombin (factor II, FII) to thrombin (FIIa). Other part of Xa forms a complex
with molecules called tissue factor pathway inhibitors 1 or 2 (TFPI-1, -2) which function as negative
feedback controllers of the extrinsic pathway (Rapaport and Rao 1995). In addition, to sustain the
coagulation process, thrombin is also formed by the intrinsic pathway, namely through the action of
FIXa in concert with its cofactor VIIIa.
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The final step in the coagulation cascade is the formation of a stabilized fibrin clot. Thrombin
produced in the coagulation process converts soluble fibrinogen consisting of pairs of three chains
Aα, Bβ, and γ to fibrin monomers by proteolytically cleaving the fibrinopeptides A and B from the
central globular region of the fibrinogen molecule. This results in fibrin (αβγ)2 Simultaneously,
thrombin activates a transglutaminase FXIII, which in turn induces the covalent cross-linking of
formed fibrin monomers to polymers in a transamidation reaction (described in the section of FXIII
in detail).
In the original coagulation cascade theory, the initiative proteins in the intrinsic pathway were the
high molecular kallikrein (HK), prekallikrein and factor XII (FXII) which were found grouped
together and named the ”contact system”, because they needed a contact with artificial, negatively
charged surfaces for zymogen activation in vitro. The contact system was considered to lead to the
activation of FXI and IX and further FX. This cascade was thought to be essential because
deficiencies in the contact pathway proteins had been shown to result in prolonged activated partial
thromboplastin time (APTT) (Colman et al. 1975, Wuepper et al. 1975, Saito et al. 1975). In
distinction to this theory, it is now believed that the activation of FXI by still some unknown agents
is the real initiative component for the intrinsic coagulation pathway and the mode of action of e.g.
FXII remains unclear (Schmaier 1997). Furthermore, it has been shown that the ”contact activation”
of the complexed HK, and prekallikrein proteins happens on injured endothelial cells by
metalloproteases (in vivo) independent of FXII (reviewed by Schmaier 1997). Interestingly, HK is a
precursor of bradykinin, which induces vasodilatation and tissue type plasminogen release, hence,
the contact system also takes part in the initiation of fibrinolysis.
Blood coagulation is inhibited at several points by such factors as TFPI-1 and TFPI-2 (Broze and
Miletich 1987, Rao 1987, Sprecher et al. 1994), protein C (Kisiel et al. 1979) with its cofactor
protein S (DiScipio and Davie 1979, Walker 1980, 1981), and antithrombin III (Rosenberg and
Damus 1973), which are all proteins produced outside of the coagulation cascade and act to prevent
generalized thrombus formation. However, regulation arising from the coagulation cascade itself
has been reported (Hanson et al. 1993), as low amounts of thrombin, generated in ongoing
coagulation cascade, increases levels of activated protein C, the inhibitor factor V, in contrast to
high levels of thrombin, which have strong procoagulant effects. This phenomenon is called the
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thrombin paradox as the same factor thus acts as an anti- and procoagulant (Griffin 1995). Also very
recently, Safa et al. (1999) have reported FVIIa/TF generated resistance to activation of FV and
further susceptibility of FV for destruction by activated protein C.
Intrinsic Pathway
Tissue Factor Pathway
XI
XIa
IX
IXa
Ca2+
Xa
X
PL
VIII
VIIIa
II
APC
Protein C
Protein S
Fibrinogen Fibrin monomer
Fibrin polymer
Fibrin clot
XIII XIIIa
Endothelial injury
Tissue Factor
VIIVIIa
TFPI
V
Va
PL
Thrombin (IIa)
IIa
IIa
IIa
Protein C inhibitor
VIIa,TF, Ca2+ 
Ca2+
Ca2+
Ca2+
Ca2+
Xa
Antithrombin III
IIa
Thrombomodulin
Ca2+
IXa
IX
Figure 2. The coagulation cascade is initiated by two pathways converging at the formation of FXa,
which triggers the formation of thrombin (IIa) from prothrombin (II). The final step in the
proteolytical activation cascade of coagulation factors involves FXIII which cross-links fibrin
molecules to a clot-stabilizing mesh over the aggregated platelets. Inhibitors of the cascade are
shown in gray.
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2.3 Endothelium
The endothelium, composed of the specific types of the vessel wall lining cells, is a dynamic,
heterogeneous, disseminated organ that possesses vital secretory, metabolic, and immunologic
functions (Fishman 1982). Endothelial cells (EC’s) play a dual role in hemostasis. On one hand, an
intact endothelium provides a fluent environment for proper circulation of blood by insulating the
strongly thrombogenic agents in the vessel wall and being non-adhesive for circulating cells. On the
other hand, the endothelial cell surface undergoes a rapid transformation from anticoagulant to
procoagulant state in response to trauma in order to maintain the intravascular volume and oxygen
delivery (for review, see Cines et al. 1998).
Upon activation of endothelial cells by an injury, ECs immediately release vasoactive agents, such
as endothelin (ET), which is the most potent inducer of vasoconstriction identified so far. Nitric
oxide (NO), another secreted product of ECs’ counteracts endothelin. It has been shown that in
states of EC dysfunction the concentrations of bioactive NO are reduced. This leads to the relatively
unopposed actions of ET which may further promote the generation of pathological vasoconstriction
and atherosclerosis formation leading to thrombophilia (Lopez et al. 1990). Other responsive
mechanisms of the activated endothelial cells are exhibited by a distinct expression of cytokines,
growth factors, and their receptors, including vascular endothelial growth factor (VEGF) and its two
tyrosine kinase receptors VEGFR-1 and -2. Furthermore, receptors for fibrin, FIX, IXa, X, Xa, FXII,
kallikrein as well as for TF, thrombin and activated protein C are expressed by ECs, all affecting the
coagulation system. The exposure of vWF produced by ECs mediates the adhesion of platelets to
the severed vessel wall. Conversely, the expression of protein S, TFPI-1 and trombomodulin by ECs
contributes to the inhibition of thrombosis (reviewed by Cines et al. 1998).
There is now extensive evidence that morphologically abnormal endothelium is also dysfunctional
and actually contributes to the propagation of lesions. This comes clearly up, for instance, in regard
to the notable augmentation of the risk to acquire pathological thrombosis in atherosclerotic vessels
compared to non-affected ones (reviewed by Ross 1976, McGorisk and Treasure 1996). A chronic
endothelial injury and activation of ECs, resulting from a continuous stress to the endothelial cells
caused by for example cigarette smoking, induce the formation of an atherosclerotic plaque. In this
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process the defected endothelium expresses adhesion molecules and monocytes, leukocytes as well
as platelets adhere to the vessel wall and increased permeability of the endothelium is observed.
Also lipid insudation from blood through ECs occurs. Later monocytes/macrophages aggregate in
the intima and smooth muscle cells migrate to the site of vascular insult. Fatty streaks and further
foam cells are formed as they engulf lipids. Furthermore, it has been shown that some growth
factors originating from endothelial cells, platelets or macrophages, which bind to the receptors on
activated endothelial cells and induce angiogenesis as well as vascular permeability, may contribute
to the atherosclerosis formation. The angiogenic effects of these growth factors are observed in
neovascularized atherosclerotic plaques in response to partially or totally occluded vessel (Inoue et
al. 1998, Beitz et al. 1991, Kuzuya et al. 1995, Chen and Henry 1997). It has also been shown that
the extent of neovascularization is correlated with the severity of atherosclerosis (Eisenstein 1991).
Conversely, the regression of an atherosclerotic lesion is accompanied by a regression of
neovascularization (Williams et al. 1988). The recent gene therapy studies with vascular endothelial
growth factor (VEGF) and upregulation of angiogenesis in ischaemic vascular diseases have been
successful (Isner et al. 1998, Losordo et al. 1998). Hence, in future also targeted gene therapy to
reduce the neointimal angiogenesis and atherosclerosis itself may be possible.
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3. Vascular endothelial growth factors VEGF and VEGF-C
Growth factors are an evolving family of molecules with multiple functions, also in response to
endothelial injury. They are produced and secreted by various tissues and cells affecting e.g. the
conditions for chemotaxis and cell mitogenesis essential also in hemostasis and further tissue repair.
Vascular endothelial growth factor (VEGF) and VEGF-C which bind to their distinct and/or shared
high affinity receptors almost exclusively expressed by ECs, are included in this family of
molecules.
3.1 Role of vascular endothelial growth factors (VEGF and VEGF-C) in physiological and
pathological processes
VEGF, also called vascular permeability factor (VPF) (Dvorak et al. 1995), was identified ten years
ago, when several studies reporting purification and identification of a novel vascular permeability
increasing endothelial cell growth factor, secreted from pituitary cells and tumors, were published
(Ferrara et al. 1989, Gospodarowicz et al. 1989, Connolly et al. 1989b, Leung et al. 1989, Keck et
al. 1989, Tisher et al. 1989, and Senger et al. 1990). Nevertheless, VEGF/VPF had already been
found earlier as an activity by Senger et al. (1983). VEGF is included in the so called platelet-
derived growth factor family, that shares a common structure of eight typically spaced cysteine
residues in their core domain (Heldin et al. 1992, 1993, Maglione et al. 1991, Olofsson et al. 1996,
Grimmond et al. 1996, Joukov et al. 1996, Lee et al. 1996, Orlandini et al. 1996). This family of
growth factors has been rapidly extending and includes also the other molecule of interest in this
study, namely rather newly identified VEGF-C, which is a close relative of VEGF (Joukov et al.
1996).
Both VEGF and VEGF-C are stimulators of angiogenesis and vascular permeability. Additionally,
VEGF-C induces lymphangiogenesis via binding to its other receptor, VEGFR-3, the expression of
which is restricted to the lymphatic endothelia of fetal and adult tissues (Kaipainen et al. 1995). The
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role of VEGF in various physiological and pathological processes involving angiogenesis and
vascular permeability has been extensively studied, whereas studies on the biological function of
VEGF-C have just started.
In the development of benign and malign tumors as well as metastasis, rheumatoid arthritis and
neovascular glaucoma (Koch et al. 1994), VEGF induced angiogenesis contributes to a negative
progress of the disease, whereas it has opposite and essential effects on embryogenesis and growth,
wound healing, and normal female menstruation (reviewed by Colville-Nash and Willoughby, 1997,
Folkman 1995 and Ferrara 1999). A lack of a single VEGF allele has been proven to be lethal for
mouse embryo, being represented by severe malformation of embryonic angiogenesis and blood
island formation. This provides the first example, in which a haploid gene dosage is sufficient to
cause lethality at the same stage as it occurs in the corresponding null animal (Camerliet et al. 1996,
Ferrara et al. 1996). Also VEGF-C knock-out mice die, the precise cause of which is still unclear
(Camerliet and Collen 1999).
A number of malignant tumors originating from colon, stomach, pancreas, kidney, bladder, breast,
and head and neck have been shown to express VEGF (Brown et al. 1993a and b, 1995, Dvorak et
al. 1995b, Salven et al. 1997a and b). Interestingly, also peripheral blood platelets have been
recently reported to express VEGF and release it during the platelet aggregation (Möhle et al. 1997,
Verheul et al. 1997, Maloney et al. 1998). These findings contribute significantly to the hypothesis
of VEGF being linked also to hematogenic spreading of tumors, as 1) increased activation and
aggregation of platelets are detected in cancerous states (Mattern et al. 1996, Francis et al. 1998,
Maloney et al. 1998), and 2) the angiogenic nature of VEGF, thus possibly secreted by platelets, is
known to be important in the development and maintenance of the microvessel density in malignant
tumors. Additionally, VEGF inhibits antigen presenting cells, such as dendritic cells and it has been
speculated whether this effect of VEGF would facilitate tumor growth by inhibiting the immune
reactions caused by malignant cells (Gabrilovich et al 1996). A very recent study reports a
mechanism, by which VEGF prevents endothelial cell apoptosis possibly contributing to the
tumorigenesis, as well (Gupta et al. 1999).
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It has been suggested that the role of VEGF might also extend to the intravascular coagulation
properties (Clauss et al. 1990, 1996, Möhle et al. 1997, Francis et al. 1998). Firstly, Brock and
colleges showed that VEGF, induces the endothelial cells to release vWF, the potent trigger of
platelet adhesion at sites of endothelial injury (Brock et al. 1991). Secondly, hypoxia stimulates both
VEGF and TF expression e.g. in tumor cells, supporting the suggestion of a close relationship
between VEGF and TF in the activation of hemostasis related to malignancies (Shweioki et al.
1992, Shoji et al. 1997 and Francis et al. 1998). Thirdly, together with the facts that platelet
aggregation occurs predominantly at sites of endothelial injury (Coller 1991), VEGF is released
during this process, and vascular permeability as well as angiogenesis are important for intimal
repair, it is suggested that VEGF has a role in thrombosis (Maloney et al. 1998, Beitz et al. 1991,
Chen and Henry 1997).
Atherosclerosis develops as a response to chronic endothelial injury and a conveys a potent risk for
arterial thrombosis, as already discussed earlier. The various steps in atherosclerosis include
adhesion and migration of different cells derived from blood or surrounding tissues, as well as,
increased permeability of vascular wall. VEGF has been shown to contribute to this process by
being a very potent permeability inducing agent and a stimulator of endothelial and mast cell
migration (Inoue et al. 1998, Dvorak et al. 1995). The promotion of monocyte chemotaxis has also
been reported (Clauss et al. 1990 and 1996).
VEGF-C was first identified as a ligand for the VEGFR-3/Flt4 receptor and thus considered almost
solely as a lymphoangiogenic growth factor due to the expression pattern of VEGFR-3 (Kaipainen
et al. 1995). Suggesting of an angiogenic nature of VEGF-C, resembling that of VEGF, are the fact
that VEGF-C binds also to another receptor, VEGFR-2, which it shares with VEGF. This receptor
has been shown to be a highly vascular permeability, EC mitogenesis and migration stimulating
molecule (reviewed by Eriksson and Alitalo 1999, Shibuya et al. 1999 and Taipale et al. 1999). The
results from studies on the effects of VEGF-C as an inducer of lymphangiogenesis or both
angiogenesis and lymphangiogenesis in vitro vary (Jeltch et al. 1997, Pepper et al. 1998). However,
it is suggested that this controversial issue may be solved when in vivo studies are performed for: 1)
pericellular environmental factors, such as various cytokine concentrations, 2) interactions between
cells, cytokines, and the extracellular matrix, and 3) hemodynamic forces (Pepper et al. 1998).
27
Interestingly, the angiogenic effect of VEGF-C was synergistic with VEGF and bFGF in vitro
emphasizing the importance of cooperating factors coordinately influencing the biological activity
of VEGF-C (Pepper et al. 1998). Only a couple of studies have been published on the biological
effects of VEGF-C in vivo so far. Both of them suggest VEGF-C to have a dual role as a regulator
of both lymphatic and vascular endothelial growth (Cao et al. 1998, Witzenbichler et al. 1998).
3.2 Signaling through specific receptors of VEGF and VEGF-C
The effects of VEGF and VEGF-C are mediated through their tyrosine kinase receptors but rather
little is known about the signaling pathways that follow the binding to the receptors (Mukhopadhyay
et al. 1998, Potts et al. 1998, Seko et al. 1998).
VEGF binds at least two receptor tyrosine kinases, VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1)
(De Vries et al, 1992, Terman et al. 1992). Additionally, Soker et al. (1998) recently described an
isoform-dependent binding of VEGF to neuropilin-1, which has been known to mediate neuronal
cell guidance and suggested that it may modulate VEGFR-1 and -2 induced angiogenesis. Both
VEGFR-1 and -2 are transmembrane tyrosine kinases and are coexpressed in endothelial cells
(reviewed by Ferrara 1999). VEGFR-1 is also expressed in monocytes (Clauss et al. 1996). Studies
with transgenic mice have demonstrated that the VEGF signaling through VEGFR-2 is essential for
vasculogenesis and early hematopoiesis, whereas VEGFR-1 is needed for proper endothelial
organization (Ferrara et al. 1996, Fong et al. 1995, Shalaby et al. 1995).
Like VEGF, VEGF-C binds to VEGFR-2 (Joukov et al. 1996). In addition, it has a specific receptor,
VEGFR-3 (Flt4), which is mainly expressed in endothelia of developing vasculature and in
lymphatic endothelia of adult tissues (Kaipainen et al. 1995). In peripheral blood, the expression
VEGFR-3 is restricted to lymphocytes and relatively rare CD34 positive cells (unpublished data of
U. Wartiovaara). There are studies showing its expression also in metastatic lymph nodes,
lymphangiomas, and Kaposi’s sarcoma (Jussila et al. 1998).
28
3.3 Molecular characteristics of VEGF and VEGF-C
3.3.1 Genes coding for VEGF and VEGF-C
VEGF shows relative homology with platelet-derived growth factor (PDGF) and a closer one with
placenta growth factor (PlGF) (Maglione et al. 1991). It was mapped to chromosome 6p12-21 by
(Vincenti et al. 1996). In the study in which the actual gene sequence of VEGF was discovered, also
three alternatively spliced forms of human VEGF were identified yielding polypeptides of 189, 165
and 121 amino acids (aa) (Tischer et al. 1991). Additionally, 206 and 145 aa forms were later found
by (Houck et al. 1991, and Poltorak et al. 1992). A heparin binding domain is found in 145, 165 and
189 isoforms. Regulation of VEGF occurs via hypoxia and various cytokines, such as PDGF-BB,
transforming growth factor β1 (TGF-β1), epidermal growth factor (EGF), keratinocyte growth
factor, tumour necrosis factor-α (TNF-α), and interleukin-6 (Cohen et al 1996, Pertovaara et al,
1994, Frank et al, 1995). Also, tumor promoting phorbol ester, Ras oncoprotein and mutant p53
tumor suppressor are potent inducers of VEGF mRNA (Grugel et al, 1995, Finkenzeller, 1995,
Kieser,et al 1994, Garrido 1993).
VEGF-C was recently found from the supernatant of PC-3 human prostatic adenocarsinoma cells
based on its activity to stimulate autophosphorylation of the fms-like tyrosine kinase (FLT-4)
(Joukov et al. 1996). The gene encoding for VEGF-C consists of seven exons spanning over 40kb
pairs of genomic DNA and is located on chromosome 4q34 in humans (Paavonen et al. 1996).
Chilov et al. (1997) has reported a putative alternatively spliced form of VEGF-C in fibrosacoma
cells lacking exon 4. The well-conserved cysteine-rich domains of the PDGF family are found in
exons 5-6. The VEGF-C gene is upregulated partly distinctly from VEGF, as hypoxia, Ras
oncoprotein and mutant p53 tumor suppressor do not induce VEGF-C mRNA (Enholm et al. 1997).
However, an increase of VEGF-C mRNA is seen in response to serum that includes several growth
factor agents, and to PDGF, EGF and TGF-β, TNF-α and interleukin-1β (Enholm et al. 1997,
Ristimäki et al. 1998).
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3.3.2 Polypeptides encoded by VEGF and VEGF-C genes
VEGF polypeptide consists of two covalently bound identical glycosylated monomers yielding
together 34 to 46 kD depending on the isoform (Connolly et al. 1989a, Ferrara and Henzel 1989,
Senger 1990). The covalent dimerization of VEGF is essential for its biological activity (Pötgens et
al. 1994). In addition to homodimerization, it also can heterodimerize with PlGF and VEGF-B.
(Maglione et al. 1991, Park et al. 1994, Di Salvo et al. 1995, Cao et al. 1996, Olofsson et al. 1996b).
Glycosylation of VEGF is not necessary for its biological activity, but it is important for efficient
secretion, however (Claffey et al. 1995, Yeo et al. 1991).The isoforms comprising 121 and 165 aa
are secreted in diffusible form, whereas the larger isoforms are mainly found bound to extracellular
heparin-containing proteoglycans (Houck et al. 1992, Park et al. 1993). The soluble VEGF 165 has
been identified as the major isoform of VEGF found in human tissues.
The open reading frame of VEGF-C cDNA encodes for a polypeptide of approximately 61kD, and
modification of a proprecursor occurs intracellularly as well as extracellularly. The most processed
form of VEGF-C has a molecular weight of 21 kD. The proteolytic processing of VEGF-C has been
well elucidated by Joukov et al. (1997) (Figure 3). In brief, after a cleavage of the 61kD
properecursors to 58kD propeptides, a covalent and apparently also non-covalent dimerization of
precursors occurs, which is followed by a cleavage dividing the dimerized precursors nearly in half.
The resulting polypeptides form a tetramer, originating from two precursor polypeptides bound to
each other (Figure 3). A variety of alternatively processed forms of VEGF-C are secreted, and it has
been suggested that they may have distinguishable roles in their capability of activating different
receptors of VEGF-C (Joukov et al. 1997).
As a characteristic for secreted proteins, the primary structure of VEGF-C and VEGF contains a
leader sequence, which is cleaved during the processing of the protein. Although comparison of
VEGF and VEGF-C genes has revealed extensive similarities in particular in exons 3 and 4, also
clear distinctions are found showing for instance, a lack of heparin binding domains in VEGF-C
gene in contrast to the VEGF145, 165 and 185 (Chilov et al 1997).
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Figure 3. Schematic model of the proteolytic processing of VEGF-C (modified from Joukov et al.
1997). The regions of the VEGF-C polypeptide are marked as follows: signal sequence, black box;
VEGF homology domain, grey box; N-terminal and C-terminal propeptides, dotted and open boxes,
respectively. The numbers indicate the molecular mass (kD) of the corresponding polypeptide in
reducing conditions. Disulfide bonds are marked as -S-S-; non-covalent bonds as dotted lanes.
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3.4 Expression pattern of VEGF and VEGF-C
The expression pattern of VEGF in human tissues and organs is very wide. VEGF is overexpressed
in benign and malign states of human body characterized by angiogenesis. It is found e.g. in
keratinocytes and a subpopulation of macrophage-like cells contributing to wound healing, psoriasis
and delayed-type hypersensitivity (Brown et al. 1992, 1995, Detmar et al. 1994) as well as in cardiac
myocytes of an ischaemic myocardium (Ladoux and Frelin 1993, Sharma et al. 1992). Interestingly,
endothelial cells suffering from hypoxia, can also produce VEGF, leading to an autocrine
potentiation of its effects (Namiki et al. 1995). Physiological angiogenesis occurs in fetal tissues,
placenta, proliferating endometrium, corpus luteum, which all widely express VEGF (reviewed by
Dvorak et al. 1995a and Ferrara and Davis-Smyth 1997). Low levels of expression have also been
found in kidneys, heart, prostate and semen and certain epithelial cells of the adrenal cortex and
lung (Berse et al. 1992, Breier et al. 1992, Monacci et al. 1993, Li et al. 1995).
The expression pattern of VEGF-C is more restricted than that of VEGF. However, VEGF-C RNA
has been found in healthy placenta, heart, muscle, ovary, and small intestine in humans (Joukov et
al. 1996). Additionally, Salven et al. (1998) have reported the expression of VEGF-C in a variety of
human benign and malignant tumors.
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Table 2. Characteristics of VEGF and VEGF-C
VEGF VEGF-C
Gene family      PDGF     PDGF
Genomic location      chr. 6p12-21     chr.4q34
Splice variants identified      5     2
Differences in regulators:
              Hypoxia      stimulates     no effect
              Ras-oncoprotein      stimulates     no effect
              p53      stimulates     no effects
Polypeptide      34-46kD     21-61kD
Dimerization      VEGF, VEGF-B,
     PlGF
    -
Secretion      contains signal
     sequence
    contains signal
    sequence
Expression pattern      very wide     more restricted
Receptors      VEGFR-1, VEGFR-2,
     neuropilin-1
    VEGFR-2, VEGFR-
     3
Examples of known effects:
         angiogenesis      +     +
         lymphangiogenesis      -     +
         vascular permeability      +     +
         chemotaxis      +     ?
upregulation of other
molecules      TF, vWF     ?
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4. Coagulation factor XIII (FXIII)
4.1 FXIII, a member of the family of transglutaminases
Coagulation factor XIII (FXIII) is a member of the transglutaminase (TGM) family of molecules.
TGMs are important enzymes widely distributed in tissues and organs in human body, which act by
cross-linking different substrates derived from body fluids or matrices, thus providing stability for
various biological structures (reviewed by Greenberg et al. 1991, Aeschlimann and Paulsson 1994).
Alternatively, they are able to catalyze the incorporation of small amines into the γ-glutamine sites
of proteins. In the cross-linking reactions induced by TGMs, Ca++ dependent acyl transfer reaction
forms covalent ε(γ-glutamyl)lysyl bonds between the γ-carboxyl group of a glutamine residue in one
polypeptide chain and the ε-amino group of a lysine residue in a second polypeptide chain with the
subsequent release of ammonia (NH3) (Figure 4). The members of the TGM family differ from each
other by their localization of expression and the specificity for glutamine residues, although some
overlapping substrates are also found (Greenberg et al. 1991, Aeschlimann and Paulsson 1994).
Examples of the critical functions of TGMs are such events as, cross-linking of fibrin over the
forming thrombus by FXIII or extracellular cross-linking of mineralized cartilage matrix by a tissue
transglutaminase (Loewy et al. 1957, Aeschlimann et al. 1993, 1996). The role of transglutaminases
in coagulation, apoptosis, chondrocyte development and keratinization are not fully characterized
yet, and studies of new properties of TGMs in the above mentioned and other biological processes
are ongoing.
Coagulation factor XIII (FXIII) is the factor responsible for the TGM functions in instant hemostasis
after an endothelial injury. It acts in the very last step of the coagulation cascade by stabilizing the
forming clot (reviewed by Muszbek et al. 1996). While the clot-stabilizing activity of an agent, later
named as FXIII, was discovered already in the 1950’s, an increasing interest and respect for its
function have been awaken just during the last few decades.
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Figure 4. Cross-linking reaction of transglutaminases (TGMs). The enzyme forms covalent bonds
between the γ-carboxyl group of a glutamine residue in one polypeptide chain and a lysyl substrate
in a second polypeptide chain with the subsequent release of ammonia (NH3).
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4.2 FXIII in disease processes
Recently, there have been significant results about the severe hemophilic consequences resulting
from an impaired FXIII enzyme (Mikkola et al. 1994-97, Seitz et al. 1996, Souri et al. 1998, Anwar
et al. 1998), as well as about its rather new, more general, role in multifactorial processes including
wound healing, tissue repair (Grinnel et al. 1984), the pathogenesis of myocardial infarction and
tumor growth (Kohler et al. 1998, Bardos et al. 1998, Francis et al. 1998). In addition to the
molecular characteristics of FXIII, the clinical focus of this section is placed on the monogenic
bleeding disorder due to FXIII deficiency, and on multifactorial myocardial infarction and
inflammatory bowel disease, in whose development FXIII may be involved.
4.2.1 FXIII deficiency
FXIII deficiency was first described by Duckert et al. (1960). It results from mutations in FXIII gene
leading to a lack of functional enzyme. The following delayed bleeding diathesis is autosomally
recessively inherited. Clinical symptoms of FXIII deficiency include umbilical cord bleeding,
excessive bruising, bleeding into muscles and joints, and intra-cranial bleedings (reviewed by Seitz
et al. 1996). Pregnancy can not be normally maintained without a substitution therapy except in the
case of the very mild phenotype (Mikkola et al. 1997a, Girolami et al. 1986, Saito et al. 1990).
Furthermore, other symptoms also vary considerably within FXIII deficient patients. Very low
plasma levels of FXIII are enough to maintain the hemostasis rendering the substitution therapy
efficient. The molecular genetic studies on characterizing the causative changes in the FXIII gene
have been successful and produced over 40 mutations (Anwar et al. 1998a, 1998b, 1998c and
reviewed by Mikkola 1997). Molecular mechanisms by which the various mutations lead to a
deficiency state are also well established (Mikkola et al. 1997b, Souri et al. 1998, Anwar et al.
1998a). FXIII consists of A and B subunits (described later in detail) and most of the mutations
leading to a defective enzyme are located in FXIII-A (Mikkola 1997).
36
4.2.2 FXIII and myocardial infarction
Myocardial infarction (MI) is the leading cause of deaths in industrialized nations. It is often an
endpoint of a long cascade of events occurring in coronary arteries. Several risk factors are known
to contribute to the pathogenesis of MI, such as cigarette smoking, hypertension, diabetes mellitus,
hyperlipidemia, hyperhomocysteinemia, reduced fibrinolytic capacity of tPA, as well as, elevated
plasma levels of FVII, fibrinogen, and PAI-1. Some of these are purely acquired, but genetic
variations are found in a significant proportion of them solely or combined with the acquired factors
being responsible for the clinical manifestations. In contrast to the number of genetic risk increasing
factors identified so far, only a few inherited gene modulations have been suggested to provide
protection against MI (Green et al. 1991, Kohler et al. 1998, Iacovello et al. 1998).
Mutations in FXIII gene have previously been associated with hemostasis mainly due to the
tendency to cause a severe bleeding diathesis resulting from a defective enzyme. Furthermore, it is
known that the polymorphisms, found in FXIII gene, do not cause clinical bleedings. The role of
these common variations in hemostasis has not been a subject of interest until recently, when a
hypothesis concerning a possible functional meaning of a valine to leucine polymorphism located
critically only three residues apart from the thrombin cleavage site of the FXIII-A activation peptide
(AP), was put forward. Kohler and his colleagues (1998) reported an inverse association of this
polymorphism (Val34Leu) with the risk of myocardial infarction and suggested a new role for FXIII
in hemostasis in polygenic thrombotic diseases. The genetic epidemiologic study was performed by
using a Caucasian patient material collected in Great Britain. The association yielded very
significant statistics and seemed to be even more prominent in patients with coronary artery disease
and thus at increased risk to acquire MI (Kohler et al. 1998). Further studies on FXIII Val34Leu and
its effects on thrombosis are now in progress and very recently Catto et al. and Franco et al. (1999)
reported its association also with venous thrombosis, thus strengthening the hypothesis of the effects
of the polymorphism on the behavior of FXIII in the coagulation. However, no studies or
suggestions on the mechanism underlying this positive effect have yet been published.
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4.2.3 FXIII and inflammatory bowel disease
An increased microthrombus formation in the necrotic areas is characteristic of inflammatory bowel
disease (IBD) and a higher incidence of thromboembolic events in the active phase of the disease
has been detected (Bargen, et al. 1936, Talbot et al. 1949, Warren et al. 1949, Edwards et al. 1964,
Sloan et al. 1950, Lam 1975). IBD includes ulcerative colitis (UC) and Crohn’s disease (CD). Both
the disorders show inflammatory areas and can be differentiated by their localization in the
intestine, as well as by the histologically identified deepness of the affected area. UC is restricted to
the colon and damages only tunica mucosa, whereas CD may be found in all sections of the
intestinal tract and shows discontinuous inflammatory reactions of all layers of the intestinal wall.
Intensive studies are performed to find characteristic markers for the disease activity and related
thrombotic diathesis and some have already been identified (Kjeldsen et al. 1998, Lake et al. 1978,
Wisen et al. 1988, Seitz et al. 1994, Oshitani et al. 1995). Decreased activity and antigen levels of
FXIII have also been reported to be associated with IBD as patients with an active disease have been
shown to have reduced FXIII activity and antigen levels that might contribute to the etiology of the
disease (Seitz et al. 1994). There are successful reports on FXIII substitution therapies in the
patients with UC or CD and it has been suggested that the decreased activity of FXIII and FXIII
deficiency would result from an increased consumption related to the extensive microthrombus
formation. However, no specific studies have been performed to verify this hypothesis. Moreover,
other explanations for the alterations of FXIII levels may also exist. These include genetic variations
in the FXIII gene that might affect the activity and antigen levels of FXIII, such as possibly FXIII
Val34Leu that is located near the thrombin cleavage site of the FXIII activation peptide and has
been associated with decreased risk of thrombosis (Kohler et al. 1998, Catto et al. 1999, Franco et
al. 1999, Board et al. 1998, Anwar et al. 1999).
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4.3 Substrates of FXIII
In order to learn about the mechanisms behind the clinical manifestations, in which FXIII is
involved, it is important to identify the substrates that FXIII is able to cross-link. The main site of
action of FXIII is indisputably in hemostasis where it stabilizes the clot. The forming clot includes
several proteins, the majority of which consist of fibrin, α2-antiplasmin, and fibronectin, that all are
substrates for FXIII.
During the formation of a fibrin clot, first, fibrinopeptides A are cleaved and released from
fibrinogen by thrombin, then formed fibrin monomers partly associate spontaneously producing
protofibrils. After expansion of these polymers, fibrinopeptide B is cleaved and fibrin molecules
become cross-linked by FXIII (Shwartz et al. 1971 and 1973, Blombäck and Blombäck 1972).
Uncleaved fibrinogen can also be cross-linked to the clot, although more slowly (Kanaide et al.
1975). As the clotting proceeds, α2-antiplasmin, which is an essential molecule for inhibition of
fibrinolysis, becomes bound to fibrin α-chains by FXIII. It appears that α2-antiplasmin comprises
both the reactive glutamines and lysines, and thus can form cross-links to itself, too (Kimura and
Aoki 1986). Fibronectin contributes ∼4% of the proteins of a clot. Both plasma and intracellular
types of fibronectin are substrates of FXIII (McDonagh 1981, Mosher and Johnson 1983).
Fibronectin is covalently cross-linked to itself and to fibrin(ogen) by FXIII but the precise functions
of these cross-links still remain unestablished. It is suggested that they may play a role in cell
migration and wound healing. In addition to being cross-linked to fibrin, fibronectin becomes bound
to various extracellular matrices by FXIII (Corbett et al. 1997, Mosher et al. 1991, Barry et al.
1988.).
Other substrates of FXIII known thus far include laminin, von Willebrand factor, vitronectin,
vinculin and intracellular actin, myosin, gelsolin, and thrombospondin but little is known about the
biology associated with the effects of FXIII on them (Mosher and Johnson 1980, Usui et al. 1993,
Tagaki et al. 1995, Francis et al. 1986, Huh et al. 1988, Jensen et al. 1993, Cohen et al. 1979, 1980,
Asijee et al. 1988, Muszbek et al. 1996).
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4.4 Activation of FXIII
FXIII has to be activated so as to be able to cross-link its substrates. During the activation of FXIII
calcium induces a dissociation of the B subunit from the FXIII-A and a cleavage of the activation
peptide from the A subunit by thrombin occurs. However, these events are not sufficient for the
catalytic core of FXIII to be exposed. Based on crystallization studies, it has been shown that the
activation peptide is cleaved but not released upon thrombin induced activation of FXIII and
additionally binding of either fibrin or Ca++ to the molecule is needed for the conformational change
to occur, and thus to expose the active site of FXIII (Yee et al. 1995 and 1996, Weiss et al. 1998). In
contrast to the activation of plasma FXIII, that of the cellular counterpart does not necessarily need
thrombin to occur, since it has been shown that some of the intracellular FXIII zymogen can be
transformed to an active enzyme (FXIIIa) due to high Ca++ concentrations during platelet activation
without any proteolytical cleavage of the activation peptide (Muszbek et al. 1993).
4.5 Expression and distribution of FXIII
The cellular FXIII is composed of an A2 dimer in distinction to the heterotetrameric form FXIII-
A2B2 in the plasma. In blood, cellular FXIII-A2 is found in megakaryocytes, platelets, monocytes,
and monocyte derived macrophages. Although it is known that platelets may internalize and
package molecules from plasma (Handagama et al. 1989), it is likely that the amounts of the cellular
FXIII-A2 found in platelets originate from their megakaryocyte precursors. Based on studies
performed with leukemia cells, Invernizzi et al. 1992 have shown some expression of FXIII-A also
in early monocytopoietic cell lineages in bone marrow.
Platelet FXIII-A is mainly a cytoplasmic protein, although there is evidence that some FXIII may
also localize to platelet granules or other releasable pool (Sixma et al. 1984). In fact, α-granules
contain minute amounts of FXIII-A2B2, which has proven to be internalized from plasma (Marx et
al. 1993). The secretion pathway of platelet FXIII-A to plasma is not mediated by normal
degranulation concerning α-granules or dense bodies as a consequence of platelet activation, and
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controversial opinions on its release either through exocytosis or microvesiculation are raised
(Holme et al. 1993). However, it is known that most of plasma FXIII-A2 originates from bone
marrow-derived cells. Poon et al. (1989) have shown a change of the plasma FXIII phenotype along
bone marrow transplantation supporting the hypothesis of the bone marrow origin of plasma FXIII-
A. Three types of liver cells, namely Kupffer cells, connective tissue histiocytes and hepatocytes
have also been shown to express FXIII-A but there has been controversy on the meaning of the liver
in producing plasma FXIII-A (Adány 1996a). It is also discussed whether the FXIII A subunit found
in the liver, reflects internalized or synthesized FXIII-A. Nevertheless, the liver is the main site of
synthesis of FXIIIB. FXIII can be found in multiple body tissues and organs e.g. placenta, in
addition to blood cells and liver, through its expression in tissue macrophages (Weisberg et al.
1987, Adány et al. 1996b).
4.6 Genes coding for FXIII
FXIII A and B subunits are coded by different genes mapped in chromosomes 6p24-25 (Board et al.
1988) and 1q31-32.1 (Webb et al. 1989), respectively. The FXIII-A gene contains a total of 15
exons and large intronic areas spanning together over 160kb (Ichinose and Davie 1988). The exons
encode for a 3.9kb mRNA with a 84bp 5’untranslated region, 2.2kb open reading frame and 1.6kb
3’untranslated region. The coding regions of FXIII-A gene have been sequenced but little is known
about the intronic areas (Grundmann et al 1986). Most of the mutations causing a defective FXIII
enzyme and thus a bleeding diathesis are found in the A subunit.
The gene coding for FXIII-B consists of 12 exons encoding for 2kb mRNA, 641aa. It has a
characteristic ten homologous repeats called Sushi domains due to their shape which contain
sequences for 60 aa each, in exons 2-11 (Ichinose et al. 1986). These domains are also known as
glycoprotein (GP) structures because of the primary identification of similar repeats in β2-
glycoprotein. Furthermore, a leader sequence coding for 20aa typical for proteins secreted through
conventional secretory pathways is found in FXIII-B. Kida et al. (1999) has demonstrated the
binding of several myeloid and ubiquitous transcription factors, such as GATA-1, ETS-1, MZF-1,
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SP-1 and NF1 into the promoter of FXIII-A. However, not much more about the transcriptional
regulation of the FXIII genes is known.
4.7 Polypeptides encoded by FXIII-A and FXIIIB genes
The molecular weight of the cellular FXIII-A2 dimer is 166kD whereas that of the plasma form
A2B2 is 320kD. An FXIII-A subunit consists of an 1) aminoterminal activation peptide (AP),
revealing 37 aminoacids, and being cleaved by thrombin at position Arg37, 2) a beta sandwich,
(residues 38-184), 3) a catalytic core (residues 185-515), 4) a barrel 1 (residues 516-628), and 5) a
barrel 2 domain (residues 629-760) (Yee et al. 1994) (Figure 5). The catalytic core comprises of
several residues absolutely conserved in the transglutaminase family which are identified to be
important for cross-linking activity and substrate specificity. These residues include e.g. Cys 314,
His 373 and Asp 396. FXIII-B has been considered to function as a carrier protein and a stabilizing
factor for the enzymatic activity conserving FXIII-A. Ten homologous sushi domains are found in
FXIII-B in accordance with the assumed function of FXIII-B, as the same kind of sushi structures
have been found in more than 20 other proteins, many of which appear to be involved in binding a
molecule to another protein (Ichinose et al.1990).
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FXIIIa
polypeptide
37
Val34Leu
184 515 628 731
β-sandwich core domain β−barrel 1 β−barrel 2activation 
peptide
Figure 5. The polypeptide profile and the three dimensional structure of FXIII-A (Cortesy of Dr.
Vivien Yee, University of Washington, Seattle, WA). The location of Val34Leu polymorphism is
represented by •.
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AIMS OF THE PRESENT STUDY
Coagulation factor XIII (FXIII) as well as vascular endothelial growth factors VEGF and VEGF-C
have thus far been known to have various roles in distinct disease processes. The aim of this study
was to broaden the knowledge about the molecular biology of these molecules, in relation to the
responses of endothelial wall injury in physiological and pathological thrombus formation. The
specified aims of this study were:
1. To evaluate if FXIII Val34Leu polymorphism would be associated with a pathological thrombus
formation in coronary vessels in Finnish patients in a population which is both genetically
isolated and has a high incidence of coronary heart disease.
 
2. To study whether FXIII Val34Leu polymorphism is associated with inflammatory bowel disease,
a disorder known to be associated with microthrombotic events.
 
3. To characterize the molecular consequences of Val34Leu polymorphism on FXIII activation.
 
4. To study the expression of angiogenic growth factors VEGF and VEGF-C in peripheral blood
cells and to provide basic knowledge for further studies of the role of VEGF and VEGF-C in
peripheral blood.
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MATERIALS AND METHODS
More detailed descriptions of the materials and methods are presented in the original publications,
which are referred to in the text by their Roman numerals (I-IV).
1. Study subjects (I-IV)
1.1 Patients and controls
A possible association of FXIII Val34Leu polymorphism with the risk of myocardial infarction (I)
was studied in two groups of subjects obtained from different sources. The first study group was
collected from the Department of Forensic Medicine of the University of Helsinki and consisted of
268 males, 68 of whom had had a myocardial infarction. The primary sample collection was
performed in the Helsinki area from 300 consecutive deaths of males from July 1991 to June 1992.
The diagnose of MI was determined by histological stainings of the myocardium and/or the presence
of a premortem coronary thrombus found in autopsies. The second group of study subjects was
recruited from patients who had undergone a coronary angiography in Helsinki University Central
Hospital (HUCH) in 1988-1989. The material used in study I included only non-diabetic males
(n=184), 58 of which had had a history of MI based on the Minnesota Code (Rose et al. 1968). The
clinical and biochemical characteristics of the study subjects are presented in Table 3. Additionally,
four DNA pools containing samples from randomly selected individuals from Lapland and the
Kainuu areas, as well as from Helsinki and south-western Finland  were used for the determination
of allele frequencies of FXIII 34Leu in Finland (see Figure 5 in the section of Results and
Discussion).
Patients used in the association study of IBD with FXIII Val34Leu and FV Arg506Gln (Leiden)
mutation (II) were recruited from the gastroenterologic units of HUCH and Maria Hospital, a
municipal hospital of the city of Helsinki, between 1995-1997. The patient material consisted of 563
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subjects, including 328 patients with ulcerative colitis and 235 patients with Crohn’s disease. A
detailed information on their disease was obtained. 120 and 142 apparently health individuals were
used as controls for FV and FXIII analysis, respectively.
Leftovers of fresh bone marrow samples were collected from acute leukemia patients at diagnosis
and used to study the mRNA expression of VEGF-C (IV).
1.2 Healthy volunteers (III, IV)
Peripheral blood was collected for further processing from healthy volunteers in order to study the
biochemical effects of FXIII Val34Leu (III) and the pattern of expression of VEGF and VEGF-C
(IV).
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Table 3. Clinical and biochemical characteristics of study subjects used in study I. Means and
standard deviations or percentages are presented in parentheses.
Autopsy series Hospital patients
Myocardial
infarction
No myocardial
infarction
myocardial
infarction
No myocardial
infarction
n= 68 n= 218 n= 58 n= 126
Age 58.3 (8.0) 50 (9.2) 56.3 (8.1) 54.4 (10.8)
body mass index
(kg/m2)
26.2 (4.8) 24.7 (5.1) 27.7 (3.5) 26.7 (3.5)
history of smoking - - 43 (74%) 83 (65%)
cholesterol
(mmol/l)
- - 5.8 (1.3) 6.0 (1.4)
triglycerides - - 1.8 (1.2) 1.7 (0.8)
HDL-cholesterol - - 1.0 (0.3) 1.1 (0.3)
2. Cell and plasma collection (I-IV)
Peripheral blood (I, II, III, IV) and bone marrow (IV) samples were collected for analyses to identify
FXIII Val34Leu and PAI-I 4G/5G polymorphisms and to study the molecular biology of FXIII,
VEGF, and VEGF-C. Ammonium chloride or Percoll gradient centrifugation was performed for
extraction of leukocyte or mononuclear cell pools. For a more strict fractionation, various methods
described in Table 4 were used. Platelet-poor plasma was obtained by centrifuging peripheral blood
samples.
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Table 4. Methods for cell extraction and further purification.
Cell fraction                                Method                                              Reference                        Study
granulocytes                       gradient centrifugation                       Syrjälä 1985                                IV
T-lymphocytes                   Percoll and miniMACS sorting          Ganshirt-Ahlert et al. 1992         IV
B-lymphocytes                   Percoll and miniMACS sorting          Ganshirt-Ahlert et al. 1992         IV
monocytes                          Percoll and miniMACS sorting          Ganshirt-Ahlert et al. 1992         IV
platelets                              gel filtration                                        Siljander et al. 1996              III, IV
CD34+                               Percoll and miniMACS                       Miltenyi et al. 1994                    IV
3. Detection of the FXIII Val34Leu and PAI-I 4G/5G polymorphisms (I)
DNA was extracted from peripheral blood of patients and controls (I, II) and healthy volunteers (III)
by standard procedures. For screening of the allele frequencies in the study materials, genotyping
was carried out using the accurate solid-phase minisequencing method as earlier described by
Syvänen et al. (1990) and Ihalainen et al. (1994) (I, II, III). The primers used are listed in the
original paper I. The geographical distribution of FXIII Val34Leu and PAI-I 4G/5G was established
by calculating the fraction of the specific alleles in pooled samples analyzed by solid phase
minisequencing as well (Syvänen et al. 1993).
4. Statistical analyses (I, II)
χ2-test was performed for comparison of the allele distributions and t-test for the comparison of the
means by using STATISTICA/Mac or PMDP software in both the epidemiologic studies (I, II).
Additionally, a logistic regression model was used in study I. In this analysis Val-Leu and Leu-Leu
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genotypes were pooled. The control groups’ genotype distributions were in the Hardy-Weinberg
equilibrium (I, II).
5. Analysis of the effects of Val34Leu polymorphism (III)
5.1 Expression of the FXIII Val34Leu in vitro
To study the stability of FXIII Val34Leu polymorphism and its nature in vitro (III), an expression
construct was created. FXIII cDNA was inserted into SV40poly expression vector and the Val34Leu
mutation was constructed by a specific oligonucleotide. The mutant and wild type cDNA clones
were used for transfection of COS-cells by the DEAE-dextran-chloroquine method or CaPO4
precipitation (Sussman and Milman 1984). The stability of Val34Leu mutant was studied by pulse-
chase analysis in which the cells were starved in methionine free medium for 15 min and subjected
to a 1 hour pulse with 200mCi 35S-methionine. Subsequently, the cells were monitored after
variable chase periods (4, 8, 24 hours). Thereafter, FXIII proteins were immunoprecipitated from
the cells and run on SDS-PAGE. Autoradiography was used for the visualization of the
polypeptides.
5.2 Studies on the activation of FXIII Val34Leu
The Val34Leu polymorphism is located very near the thrombin cleavage site of the activation
peptide that is considered to lead to the enzyme activity of FXIII-A (Muszbek et al. 1996). Hence, it
was hypothesized that the amino acid change might alter the susceptibility of FXIII to thrombin
cleavage of the activation peptide and the cross-linking character of the enzyme. The possible
genotype-correlated variations in these molecular events were studied using transfected COS-cells
supplying a source of FXIII without interference of other hemostatic variations. Additionally, gel-
filtered platelets (GFP) isolated from individuals of different FXIII Val34Leu genotype were used to
check the reproducibility of the results obtained from conditions provided by COS-cells.
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The cleavage of the COS- cell or platelet-derived FXIII activation peptide was induced by thrombin
and Ca++  with and without fibrinogen at incubation for variable time periods at +37 °C. Thereafter,
Western blotting and enhanced chemiluminescence (ECL) with anti-FXIII antibody were used to
visualize the accumulation of the activated FXIII lacking the activation peptide. The distinctions in
the accumulation rate were confirmed by densitometry. FXIII has multiple substrates of which fibrin
is the most important for its clot-stabilizing nature. In order to study whether the Val34Leu had
effects on the fibrin cross-linking capacity following the cleavage of the activation peptide,
thrombin and Ca++activated COS-cell-derived samples were run on SDS-PAGE. The formation of
fibrin γ-γ dimers and high molecular weight α-polymers along with time was monitored by staining
the gels with Coomassie blue. Furthermore, the enzymatic activity of wild type and Val34Leu
mutant FXIII was measured in COS-cell samples using [H3] putrescine incorporation filter paper
assay and a commercial Berichrom FXIII kit (Behring Diagnostics GmbH, Marburg, Germany) as
described earlier (Lorand et al. 1972 and Fickensher et al. 1991).
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6. Analysis of VEGF and VEGF-C expression in blood cells
Various cell fractions were used as a source of RNA to describe the expression pattern of VEGF and
VEGF-C in blood (IV). Samples drawn from leukemia patients were used as a tool to find a possible
lineage specificity already in immature blood cells. Total RNA was extracted from blood cells and
bone marrow samples using a commercial RNAzolB kit (Tel-test, Friendswood, Inc., TX). The
mRNA expression was studied by performing the reverse transcriptase polymerase chain reaction
(RT-PCR) and subsequent blotting and hybridization with a specific αP32dGTP or CTP -labeled
nucleotide. A control RT-PCR detecting CD3 expression, which is a specific marker of T-cells, was
performed to exclude a possible T-lymphocyte contamination in the platelet preparations. To study
the expression of VEGF-C polypeptide, gel-filtered platelets and leukocytes from a patient with
idiopathic thrombocytopenia were subjected to Western blotting and ECL with an anti-VEGF-C
antibody. In order to monitor the possible release of VEGF-C protein from platelets, they were
activated by thrombin receptor activating peptide (SFLLRN) and included in the analyses with the
related supernatant and a control supernatant from non-activated platelets.
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RESULTS AND DISCUSSION
1. Identification of FXIII Val34Leu as a beneficial factor against myocardial infarction (I)
Myocardial infarction (MI) is an endpoint of a complex thrombotic disease in the development of
which pathological modulations in coagulation and fibrinolytic cascades have been proved of
importance. These include for example, elevated levels of fibrinogen, FVII and vWF and
plasminogen activator inhibitor 1 (PAI-1), often due to various modulations in the corresponding
genes (Grant and Prentice 1994). Additionally, several environmental factors and life style
contribute to the disease. Educational programs conducted in Finland have been successful and
decreased coronary incidences significantly (Vartiainen et al. 1994). As the risk factors related to the
environment and life style have thus been reduced, and Finland still is one of the leading nations for
the prevalence of CAD in the world, the role of genetic variations becomes even more interesting.
Nevertheless, the studies on the parental history as an independent risk factor for coronary
incidences have suggested a more implicit importance of genetic factors in populations with a low
disease incidence (Jousilahti et al. 1996).
In study I, the possibility that Val34Leu polymorphism in the FXIII gene might contribute to the
pathogenesis of a thrombotic disorder was studied at the epidemiological level in Finland. The
association analysis between FXIII Val34Leu and MI was carried out in two independent study
groups with various anamnestical parameters describing for example patients’ history of smoking or
severity of atherosclerosis in their coronary vessels (Table 3). The study groups including men with
or without a known history of myocardial infarction were collected from the Forensic Department of
the University of Helsinki and HUCH and genotyped for FXIII Val34Leu and PAI-1 4G/5G. The
study structure was unique including both patients that survived MI and those that had died because
of it, thus decreasing the possible selection bias caused by survival/mortality. The association
analysis showed that the FXIII Leu34 allele was significantly more prevalent in individuals without
a history of MI than in those with MI in both study groups (Table 5). In the series collected from the
forensic department 29% of the MI cases and 43% of the controls were heterozygous or
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homozygous for the Val34Leu polymorphism at a level of statistical significance of p=0.03. In the
logistic regression analysis, the adjusted odds ratio (OR) was 0.5 (95% CI 0.26-0.94). In the hospital
series of patients and controls, 33% of the patients with a history of MI and 45% of the controls
were of the Val-Leu or Leu-Leu genotype (p=0.17). The adjusted OR was 0.61 (95% CI0.31-1.23).
When the two datasets were combined, the OR was 0.59 (95% CI 0.38-0.93) and p= 0.02 (Table 5).
The same tendency of a lesser number of individuals carrying the Val34Leu polymorphism in
patients with MI in distinction to controls was detected when allele frequencies were compared
(Table 5). Combining the materials raised the statistical power as well. The distributions of allele
frequencies, genotypes, and odds ratios were surprisingly similar in both study groups. The results
implied that in the subjects studied the risk of getting a myocardial infarction was decreased almost
by half if one carried the Leu-allele. This strongly supported the primary hypothesis suggested by
Kohler et al. (1998).
Myocardial infarction is a complex disease caused by the sum of several factors and their
interactions, also at the molecular level. One of the most studied and controversial molecules
contributing to the thrombophilia at the moment, is plasminogen activator inhibitor 1 (PAI-1). The
elevations of PAI-1, possibly due to the 4G/5G mutation in its promoter, have been shown to
associate with increased thrombophilia (ECAT Angina Pectoris Study Group 1993, Hamsten et al.
1987, Mehta et al. 1987, Landin et al. 1990, Mansfield et al. 1995a, b). The interaction of PAI-1
4G/5G with the suggested protective allele, FXIII 34Leu, was analyzed, as in the earlier report by
Kohler et al. (1998) investigating the association of Val34Leu with MI in British subjects, PAI-1
4G/4G genotype seemed to cancel the beneficial effect of FXIII Val34Leu. The interaction analyses
were done only for combined subject groups due to the low number of individuals with MI who
carried the 34Leu allele and subsequent unsatisfactory statistical power in subgroup analyses. The
distribution of the PAI-1 4G/4G genotype among 34Leu carriers with (n=15, 38%) or without MI
(n= 50, 35%) did not differ significantly from each other (p=0.66) and thus appeared to have no
importance. However, it has to be noted that the power of the study significantly decreased because
of the restricted distribution of 34Leu allele in patients with myocardial infarction. There may also
be interactions with other polymorphisms present in the same gene or nearby genes, as was reported
for the two paraoxonase genes (PON1 and PON2) that are associated with the risk of CAD
(Sanghera et al. 1998). However, no other interactions other than that of PAI-1 were studied, as our
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hypothesis on the role of Val34Leu polymorphism was based on a physiological background due to
its critical location near the thrombin cleavage site of the activation peptide. It is clear that this does
not exclude the possibility of the existence of functional interactions of other FXIII polymorphisms
with Val34Leu.
Extensive studies are needed to confirm the association of an independent genetic risk factor with a
thrombotic disorder. The mutation in FV gene (Arg506Gln, FV Leiden) is one of the few
indisputable genetic thrombophilic risk factors identified thus far. In addition to large prospective
studies and meta-analyses, also the mechanism by which the FV Leiden mutation leads to a
pathological thrombogeneity has been recognized (reviewed by Bauer et al. 1998). Likewise, many
more, preferentially prospective, epidemiological studies and concurrent investigations on the
biochemical character of Val34Leu, have to be performed to confirm the suggested protective role
of this polymorphism in pathological thrombosis. The establishment of the clinical effects of FXIII
Val34Leu is important. It represents an example of an old molecule whose significance in
hemostasis was already thought to be solved, but which now presents a broadened biological
significance giving insights into the pathogenesis of a multifactorial thrombotic disease. This may
lead to further intensified research into its function, possibly in other pathological or physiological
processes thus increasing the basic knowledge of molecular biology and genetics associated with
diseases.
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Table 5. The genotype distributions and allele frequencies of the FXIII Val34Leu in subjects with or
without a history of myocardial infarction (MI).
The autopsy
series
The hospital
patients
Combined
Genotype MI no MI MI no MI MI no MI
        Val-Val 48 (71%) 126 (58%) 39 (67%) 69 (55%) 87 (69%) 195 (57%)
Val-Leu 18 (26%) 80 (37%) 18 (31%) 48 (38%) 36 (29%) 128 (37%)
Leu-Leu 2 (3%) 12 (6%) 1 (2%) 9 (7%) 3 (2%) 21 (6%)
Total no. of
individuals
68 218 58 126 126 344
Adjusted p-
value
0.03 0.17 0.02
Odds ratio
95%CI
0.5
0.26-0.94
0.61
0.31-1.23
0.59
0.38-0.93
Allele
frequencies
Val 114 (84%) 332 (76%) 96 (83%) 186 (74%) 210 (83%) 518 (75%)
Leu 22 (16%) 104 (24%) 20 (17%) 66 (26%) 42 (17%) 170 (25%)
p-value 0.06 0.06 0.009
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2. The geographical distribution of FXIII Val34Leu and PAI-I 4G/5G (I)
Finland is a country that has many benefits to study complex genetic diseases, such as myocardial
infarction due to the high prevalence of CAD and multiple characteristics of a genetic isolate.
Nevertheless, there has been some speculation concerning the unity of the genetic isolation of Finns
(Eriksson 1973, Meinander 1973, Norio 1981) and in a recent study dual origins of Finns was
suggested by Kittles et al. (1998). A divergence of haplotypes in Y chromosome was found in early
and late settlement areas of Finland representing two major founding Y chromosome lineages.
Interestingly, our results concerning the geographical distribution of FXIII 34Leu allele frequency,
studied in random population samples from different settlement areas followed quite the same
pattern as was reported for Y chromosome haplotypes. The FXIII 34Leu allele frequency was 13%
in the north-eastern area (Kainuu), whereas the other pools revealed 21-28% (Figure 5). A division
of the Finnish population has also been demonstrated by the concentrated distribution of specific
mutations resulting in familial hypercholesterolemia in the east (Kontula et al. 1992) and thus
adding to the higher risk of coronary artery diseases compared to the western parts of Finland.
However, there are some genetic variations such as insertion/deletion polymorphism in the ACE
gene (Perola et al. 1995) whose role in the pathogenesis of heart diseases is under discussion, but
which do not follow the above mentioned pattern of eastern-western distribution. This was also the
case with the other polymorphism (PAI-1 4G/5G) analyzed in the study I. In contrast to the FXIII
34Leu allele frequencies, the PAI-1 4G allele was only slightly more prevalent in North-East (55%)
compared to the other areas analyzed (47%-48%) (Figure 6). This difference was not statistically
significant.
The interesting finding of the low FXIII 34Leu allele frequency in the Kainuu area, which belongs
to the eastern high risk areas of coronary incidences, supports the association shown between FXIII
Val34Leu and the decreased risk of MI. However, it must be considered that due to the unknown
origin of the subjects, it can not be totally excluded, that eastern immigrants were over-represented
in the selection of MI patients in the association material, and thus might cause a selection bias.
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Figure 6. A map of Finland showing the distribution of FXIII 34Leu and PAI-1 4G alleles analyzed
in DNA pools gathered from four distinct settlement areas of Finland (shaded).
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3. FXIII Val34Leu and Factor V Leiden in inflammatory bowel disease (II)
An extended potential of hemostasis and microthrombus formation have been detected in active
inflammatory bowel disease (IBD) including colitis ulcerosa (CU) and Crohn’s disease (CD).
Laboratory abnormalities reflecting this, include increased levels of FV and reduced FXIII A antigen
and activity levels (Lake et al. 1978, Wisen et al. 1988, Seitz et al. 1994, Oshitani et al. 1995). The
alterations seem to correlate with the severity of the disease and have been suggested to result from
an activated inflammation in the bowel. In our study II, the role of FV Leiden mutation and
Val34Leu polymorphism in the progression of IBD were studied. FV Leiden has been
acknowledged to act as a strongly thrombophilic mutation which might associate with the
hypercoagulability found in active IBD. Moreover, it was hypothesized that Val34Leu might affect
the activity levels of FXIII and thus affect the disease. However, no FXIII Val34Leu or FV Leiden
genotype related correlation to the activity of IBD was detected in the analyses (Table 6). The allele
frequencies of the FXIII 34Leu were extremely similar in patients and controls (22.5% and 21.7%,
respectively) and the genotype distribution did not differ from patients to controls either. This might
support the previously reported hypothesis that the variations in the FXIII activity and antigen levels
mainly result from the increased formation of microthrombi and accelerated turnover of the FXIII
(Seitz et al. 1994). The distribution of FV Leiden mutation in relation to IBD revealed also negative
results, as 4.5% of the IBD patients carried the risk allele compared to the 2.1% detected in control
population. These frequencies did not differ statistically significantly. The results were in contrast
with the results from a recent study of Probert et al. (1997) where an association of IBD with FV
Leiden was reported in a UK population comprising 54 unrelated IBD patients. No clear
explanations for the discrepancy exists. The statistical power of our study was, however, stronger
including more cases for detection of a possible association of the FV Leiden with IBD.
Finnish population has been exceptionally isolated for long time and internal (or external)
immigration has been very minor until World War II, resulting in concentration of certain genetic
and environmental risk factors in special areas and people. This may lead to a divergence of
etiological factors of some diseases in Finland compared to the patterns identified elsewhere in the
world. However, this may not be the case concerning FV Leiden and FXIII Val34Leu, because their
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allele frequencies in Finland are fairly similar with those reported in other parts of Europe.
Furthermore, the meaning of single alleles in the pathogenesis of mutlifactorial diseases such as
IBD, should not be simplified.
Table 6. Distribution of Factor V Leiden mutation and FXIII Val34Leu polymorphism in patients
with IBD and control individuals
                          Factor V Leiden                      Factor XIII Val34Leu
FV
Leiden
carriers
FV wild type Total Leu34/Leu Val34/Leu Val34/Val Total
Patients
UC 17 (5.2%) 307 (94.8%) 324 19 (6.1%) 106 (34.2%) 185 (59.7) 310
CD 8(3.4%) 226 (96.6%) 234 11 (5.0%) 73 (33.0%) 137 (62.0%) 221
UC+CD 25 (4.5%) 533 (95.5%) 558 30 (5.7%) 179 (33.7%) 322 (60.6%) 531
Controls
Group 1 3 (2.1%) 139 (97.9%) 142 ND ND ND
Group 2 ND ND 4 (3.3%) 44 (36.7%) 72 (60.0%) 120
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4. Effect of Val34Leu on FXIII (III)
Based on the common prevalence in healthy individuals it is known that the Val34Leu
polymorphism in the FXIII gene does not cause a bleeding disease (Mikkola et al. 1994, Kohler et
al. 1998). Still, it may have a role in multifactorial thrombotic diseases as has recently been
suggested by Kohler et al. (1998), Catto et al. (1999), Franco et al. (1999) and Wartiovaara et al.
(1999) (I). In these studies an inverse association of FXIII Val34Leu with arterial and venous
thrombosis was reported.
In the study III the properties of the mutated FXIII were investigated in vitro by using transfected
COS-cells as a source of FXIII, because COS-cells provide a tool to study the effects of mutations
without confounding hemostatic variations. A pulse-chase analysis in which the transfected cells
were starved for 15 min and subjected to a 1 hour pulse followed by variable chase periods was
performed to investigate the stability of the FXIII Val34Leu enzyme. No increase in the degradation
of intracellular FXIII Val34Leu was detected compared to the wild type FXIII reflecting the stability
of the Val34Leu mutant enzyme.
As the polymorphism lies very near the thrombin cleavage site of the activation peptide (AP) it was
hypothesized that Val34Leu might affect the activation process of FXIII. Possible effects of
Val34Leu on the cleavage of the FXIII activation peptide were investigated by activating the
transfected COS-cells with thrombin and Ca++ and monitoring the accumulation of the shorter FXIII
fragment lacking the AP after variable time periods. The rate of the cleavage reaction was
interestingly found to be more rapid in mutated FXIII. The differences were measured by
densitometry and the results showed that after three minutes of activation 45% of the FXIII
Val34Leu molecules lacked the AP whereas in wild type FXIII this was the case only in 10% of the
molecules (Figure 8). In order to study whether this phenomenon could be reproduced also in
environment with possible confounding hemostatic variations, human platelets isolated from
individuals of different genotypes of FXIII Val34Leu were used as a source of FXIII and subjected
to activation (Figure 7). The results followed the pattern that were seen in the experiments using
COS-cells: In wild type (Val34/Val34) FXIII-A, the cleavage of the AP had occurred in 10-15% of
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the molecules, whereas in heterozygous (wt/34Leu) and homozygous (Leu34/Leu34) it was seen in
25-29% and 42-50%, respectively, after three minutes of activation (Figure 8).
Due to the beneficial effects of Val34Leu against pathological thrombus formation seen in
epidemiological studies (Kohler et al. 1998, Catto et al. 1999, Franco et al. 1999, Wartiovaara et al.
1999) the primary hypothesis on the cleavage assays was a decrease in the cleavage rate of the
activation peptide and a possible hindrance to the clot stabilizing function of FXIII. The opposite
findings lead us to more complex thoughts about the mechanisms underlying the suggested
protective effect of Val34Leu against pathological thrombosis. There is evidence that the activation
peptide cleaved from FXIII does not readily dissociate from the rest of FXIII-A protein and may
have some functional importance (Yee et al. 1995). Hence, the more rapidly cleaved FXIII
Val34Leu AP might influence the behavior of activated FXIII.
Cleavage of the activation peptide and fibrin cross-link formation have been considered as
consequential events during the activation of the FXIII. Hence, a functional mutation located nearby
the cleavage site of the activation peptide, such as Val34Leu, might also affect the cross-linking
process catalyzed by FXIII-A. The pattern of the formation of fibrin γ-γ chain and high molecular
weight α-chain cross-links induced by FXIII was thus investigated using COS-cell samples as a
source of FXIII. The samples were activated for variable time periods and the cross-link formation
observed by Coomassie-blue staining. Interestingly, compared with the wild type FXIII, the α-
polymerization occurred more rapidly in the mutant samples, whereas the γ-γ-dimerization was
found to be very uniform in both genoypes. The γ-γ chain cross-linking is a very rapid process and it
is possible that the variations may be fainted by technical reasons. Furthermore, the cross-linking of
the fibrin α-chains is more important to the clot stability than the γ-γ dimerization. There are various
enzymatic assays that can be used to measure the cross-linking activity of FXIII. In this study we
used two different methods (Putrescine and Berichrom assays) in which different synthetic peptides
are used as substrates for FXIII. Measured by both assays, the Val34Leu polymorphism was seen to
cause a significantly increased activity of FXIII. The findings were in concordance with the two
very recent reports on the increased activity levels of FXIII Val34Leu in plasma (Kangsadalampai et
61
al. 1998, Anwar et al. 1999) and correlated to our results from the assays characterizing the fibrin
cross-linking capacity of FXIII-A and cleavage of the AP from the enzyme.
The findings concerning the effects of Val34Leu on the activation of FXIII-A are interesting and
show a potentially more active variant of FXIII enzyme, which paradoxically -based on previous
results- is associated with a decreased risk of pathological thrombosis. In an acute myocardial
infarction, the fatal lesions in the heart muscle are produced due to ishaemia, often lasting for hours.
When thinking about possible mechanisms behind the paradox, it might be speculated that an
enhanced rate of clot formation might induce feedback signaling and fibrinolysis and thus shorten
the ishaemic time and prevent heart from injuries. The possibility of various interactions of the
active FXIII Val34Leu occurring in vivo, such as with the FXIII-B subunit or the cleaved activation
peptide itself, which may influence the final levels and function of FXIII are also worth concidering.
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Figure 7. Cleavage of the FXIII-A activation peptide in gel-filtered platelets (GFP) analyzed by
Western blotting under reduced conditions. (Two individuals/genotype are shown). The intact
FXIII-A is seen as a band representing a molecular weight of 83kD. A shorter FXIII fragment
missing the 4kD activation peptide (79kD) reflects the activated form of FXIII-A The accumulation
of the shorter fragment is seen at earlier time points in FXIII wt/V34L and FXIII V34L compared to
wild type FXIII (wt).
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Figure 8. The proportion (%) of FXIII molecules from which the cleavage of the activation peptide
has occurred (FXIII’) after three minutes of activation. The percentages are measured from Western
blot films by densitometry. A distinct difference in the cleavage rate is seen between the wild type
FXIII (wt), wt/V34L and V34L samples obtained from GFP isolated from different individuals and
transfected COS-cells.
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5. VEGF and VEGF-C in blood cells (IV)
Vascular endothelium plays an important role in hemostasis. There are several growth factors
identified to affect its functions including VEGF and VEGF-C, which take part in various
physiological and pathological processes involved with angiogenesis and vascular permeability.
Additionally, at least VEGF acts as a chemotactic agent and is capable of inducing the expression of
a number of molecules including ones involved in hemostasis. VEGF and VEGF-C belong to the
same family of genes and share homologous domains in their structure. They also bind to a common
receptor. This may imply, that the biological functions of VEGF and VEGF-C may be similar.
However, as VEGF-C is a newly identified molecule its biological function still remains to be
solved.
In the study IV, the expression of VEGF and VEGF-C mRNA were analyzed in peripheral blood
cell fractions of healthy adults and in CD34+ cells from cord blood representing haematopoietic
progenitor cells. Additionally, the expression of VEGF-C was studied in leukemic cells to look for a
possible lineage specificity of the molecule in immature blood cells. While VEGF was abundantly
observed in every normal blood cell fraction analyzed, VEGF-C showed a restricted pattern of
mRNA expression only in T-cells, platelets and CD34+ cells. However, no lineage specificity was
detected in the samples collected from leukemia patients and thus no conclusions about a potential
early hematopoietic lineage commitment in the expression of VEGF-C could be made.
Due to the interesting finding of platelets expressing both VEGF and VEGF-C mRNA (IV) the
protein expression of VEGF and VEGF-C in blood cells was investigated focusing on platelets (and
additionally on lymphocytes in the case of VEGF-C). It was hypothesized that if any VEGF or
VEGF-C protein were found, they would be secreted in association with the activation of platelets,
which in turn would be logical, concerning the known angiogenic functions of VEGF in e.g. tissue
repair. This hypothesis was investigated by activating the platelet homogenates with thrombin
receptor activating peptide. A leakage of the VEGF and VEGF-C concomitantly with the α-granule
pool to the supernatant of platelets was observed (Figure 9, Table 7). One could speculate that also
other than α-granule storage pools may contain VEGF and VEGF-C as no direct analysis reflecting
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the localization of them was performed. Because of the capability of platelets to internalize
molecules from plasma it also has to be considered that not all of the proteins stored in the granules
originate from platelets. However, results from mRNA studies in megakaryocytes (Möhle et al.
1997) and here in platelets suggest that at least some VEGF and VEGF-C are endogenously
synthesized.
Platelet-derived growth factor (PDGF) is a well-known relative molecule of VEGF, which has a
strong angiogenic nature. In addition to a variety of other molecules PDGF is expressed by
megakaryocytes and platelets. Its action is focused on growth stimulation of vascular wall
fibroblasts and smooth muscle cells, whereas the effects of VEGF are specific for endothelial cells
in angiogenesis. PDGF is contained in α-granules and secreted during activation of platelets. In the
study IV, the intracellular concentration of VEGF was measured by ELISA and yielded 0.003
µg/1x109 resting platelets, which is roughly similar to that described for PDGF (Niewiearowski
1994). In respect with the known biological effects of PDGF secreted from platelets in various
physiological and pathological processes the finding of the amount of platelet VEGF may suggest a
role for it also as a biologically active platelet protein.
Platelets as well as T-lymphocytes were found to secrete only an immature, 31 kD form of VEGF-C
(see Figure 3), which is thought to preferentially bind VEGFR-3 (Joukov et al. 1997). However, as
the proteolytic processing of VEGF-C occurs partially extracellularly leading to more processed
forms that also bind VEGFR-2, one can not assume the effects of VEGF-C secreted from platelets
to be restricted to lymphangiogenesis based on this finding.
Despite the known role of platelets in the repair of damaged vascular intima (Coller et al. 1991)
there is rather little known regarding the endothelial mitogens within platelets. However, the results
from this study together with the fact that platelet aggregation and activation occurs predominantly
at sites of endothelial injury, may suggest that platelet VEGF and VEGF-C are mediators in the
repair process following an endothelial injury. It is also conceivable that platelet-borne VEGF and
VEGF-C may contribute to the heightened endothelial permeability seen in processes such as sepsis
with disseminated intravascular coagulation (Parillo et al. 1990). Platelet VEGFs may also be
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involved in the progression of the endothelial disease often seen at sites of chronic
microthrombosis, such as in inflammatory bowel disease.
Increased levels of VEGF and VEGF-C have been measured from the serum of patients with
various neoplasias. In these cases the VEGF and VEGF-C were previously considered to originate
from malignant cells as the expression of VEGF and VEGF-C by cancer cells have been shown in
several studies (reviewed by Ferrara 1999). However, based on our results and those of other very
recent studies (Banks et al. 1998, Maloney et al. 1998, Pinedo et al. 1999, Vermeylen et al. 1999), it
is worth considering that some of the increase in the serum levels might also result from the
activation of platelets and further thrombosis along with the malignancy. Although very speculative,
the release of VEGF and possibly also VEGF-C might thus contribute to the hematogenic spreading
of cancer, as both molecules induce vascular permeability when released from the aggregated
platelets to bind VEGFR-2. This might then facilitate the insudation of fibrin and other molecules,
such as FXIII, from plasma. The fibrin thereafter becomes extravascularly cross-linked by FXIII,
providing a gel matrix for tumor growth (reviewed by Francis et al. 1998). Also speculatively, the
secreted VEGF and perhaps VEGF-C may contribute to the thrombophilia related to malignancies
by providing a positive feedback loop in regard to the stimulation of TF and vWF expression (Brock
et al. 1991, Shoji et al. 1998) and thus sway the hemostatic balance towards pathological thrombus
formation.
The development of an atherosclerotic plaque is also associated with neovascularization in the
thickened intima and media of vascular wall. Neovascularization may also have a role in the
progression of the plaque formation as well as in the development of intraplaque hemorrhage which
may lead to fatal consequences e.g. in coronary arteries (Inoue et al. 1998, Kumar et al. 1992)
Interestingly, Kuzuya et al. (1995) and Inoue et al. (1998) have reported a possible role of VEGF in
the formation of an atherosclerotic plaque. From the viewpoint based on the results revealed in
study IV one may speculate if also platelet-derived VEGF and VEGF-C might additionally be
involved in several phases of the processes leading to the formation of atherosclerotic plaques
following a chronic endothelial injury. In comparison with the known effects of T-cells in
association with the pathogenesis of myocardial infarction and angiogenesis related to the rupture of
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an atherosclerotic plaque (Boyle 1997, van der Wal et al. 1998), one may speculate whether T-cell-
derived VEGF-C might also contribute to these thrombotic processes.
Figure 9. Expression of VEGF-C polypeptide in peripheral blood platelets and its secretion after
thrombin receptor stimulation. Shown is a Western blot. Lane 1. Resting platelets; 2. Activated
platelets; 3. Supernatant from resting platelets; 4. Supernatant from activated platelets; 5.
Leukocytes collected from a patient with idiopathic thrombocytopenia; 6. Negative control (medium
from MCF-7 cells); 7. VEGF-C positive control (21 kD mature polypeptide from yeast); 8. VEGF-C
positive control (32kD from yeast).
Table 7. VEGF concentrations (pg/ml) measured in homogenates of 30x106 resting and activated
platelets and their supernatants collected from the peripheral blood of a healthy donor.
       VEGF (pg/ml)
    resting platelets                          457
    supernatant                          43
    activated platelets                           274
    supernatant                           468
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SUMMARY AND CONCLUSIONS
Pathological vascular events and thrombosis are associated with various diseases in human body
including myocardial infarction, inflammatory bowel disease as well as cancers. The modulations
are not restricted to the vascular wall only but extend also to the circulating and wound marginating
cells. Along with the development of technology and information about biology it has been possible
to study the events more precisely to the molecular level. This work focuses on the molecular
biology of FXIII, VEGF and VEGF-C apparently related to the immediate consequences of an
endothelial injury in the vascular environment - FXIII in the coagulation cascade, VEGF and VEGF-
C in the blood cells and vessel wall endothelium.
FXIII has been known since 1950’s but an understanding of its exact biology in the hemostatic
process only begun to emerge in this decade. The molecular genetics of the FXIII deficiency is well
characterized while very little is known about the effects of the common genetic variations in the
FXIII gene. In this work the focus was on a specific polymorphism Val34Leu which is located in a
functionally interesting site of the molecule. Its role in the pathogenesis of myocardial infarction,
which is a multifactorial thrombotic disease, and in IBD, in which activated hemostasis and
microthrombus formation occur, was investigated at the epidemiological level in Finland. An
interesting association with a decreased risk of myocardial infarction was found. However,
Val34Leu did not seem to associate with IBD. Additionally, a variation in the distribution of the
suggested protective 34Leu allele in different geographical areas of Finland was detected, as the
frequency was significantly lower in the eastern parts of Finland compared to the other parts
analyzed. This finding supports the hypothesis of an effective gene variation in consensus with the
high risk of coronary events in eastern Finland. The positive results in the association analysis with
the pathological thrombosis in coronary arteries led us to study further the molecular consequences
of Val34Leu. The polymorphism was found to increase the cleavage rate of the activation peptide
from the enzyme and increased the enzymatic capacity of FXIII. The findings implied that Val34Leu
modifies the actions of FXIII, although the final mechanism for the beneficial effect against
pathological thrombus formation still needs further studies.
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Endothelial injury induces various simultaneously occurring processes in the vascular environment
including the release of growth factors from endothelium and blood cells. These growth factors are
often associated with malignant tumor growth as well as thrombosis. In this study, vascular
endothelial growth factor, which possibly is one of the most studied molecules at the moment in the
field of molecular biology of malignancies, and its recently identified relative VEGF-C, were
chosen to be the subject of our studies, as their expression and secretion pattern in peripheral blood
had not been investigated earlier. The results revealed interestingly that both molecules are present
in blood platelets and secreted during their activation. This finding supports the role of blood cell-
derived growth factors in the consequences of an endothelial injury and furthermore may possibly
link to thrombophilic effects associated with cancers.
This study focuses on the effects occurring at the molecular level in vascular environment. The
findings support a role for the Val34Leu polymorphism in FXIII gene as well as for the blood cell-
derived VEGF and VEGF-C in thrombotic processes, offering a basis for further studies to explore
in greater depth the events following an endothelial injury.
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